Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 19/20 | 0.53 |
| ▸ | NPY1R | P25929 | 11/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.53 |
| ▸ | NPY2R | P49146 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978629 | 0.96 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30213589 | 0.96 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29531964 | 0.95 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30371101 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29938491 | 0.91 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30543180 | 0.90 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30471796 | 0.90 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3952951 | 0.90 | SLC15A2 (0.44) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29875467 | 0.90 | SLC15A2 (0.44) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29875780 | 0.90 | SLC15A2 (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240247031-A1 | COMPOSITION FOR TREATING CANCER CONTAINING TELOMERASE-TARGETING GNRH ANTAGONIST-DERIVED PEPTIDE HS1002 | Research & Business Foundation Sungkyunkwan University (KR) | 2024-07-25 | — | — | US | disclosed |
| CN-116813705-A | Peptide compound, application thereof and composition containing peptide compound | 凯惠科技发展(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-109206481-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | NPY4R 14/4885NPY1R 3/4885NPY5R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.